{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:13:57Z","timestamp":1778930037046,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.jacl.2011.05.005","type":"journal-article","created":{"date-parts":[[2011,6,25]],"date-time":"2011-06-25T22:04:40Z","timestamp":1309039480000},"page":"299-307","source":"Crossref","is-referenced-by-count":30,"title":["Clinical and laboratory phenotype of patients experiencing statin intolerance attributable to myalgia"],"prefix":"10.1016","volume":"5","author":[{"given":"Leonard J.","family":"Harris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmi","family":"Thapa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabitha","family":"Pabbathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard D.","family":"Childress","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murray","family":"Heimberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Braden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marshall B.","family":"Elam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2011.05.005_bib1","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/jama.282.24.2340","article-title":"Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials","volume":"282","author":"LaRosa","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2011.05.005_bib2","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1161\/CIRCOUTCOMES.109.848473","volume":"2","author":"Ridker","year":"2009","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacl.2011.05.005_bib3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2011.05.005_bib4","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/01.CIR.0000032466.44170.44","article-title":"ACC\/AHA\/NHLBI Clinical Advisory on the Use and Safety of Statins","volume":"106","author":"Pasternak","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2011.05.005_bib5","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.163.5.553","article-title":"Risk for myopathy with statin therapy in high-risk patients","volume":"163","author":"Ballantyne","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacl.2011.05.005_bib6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"issue":"8A","key":"10.1016\/j.jacl.2011.05.005_bib7","doi-asserted-by":"crossref","first-page":"6C","DOI":"10.1016\/j.amjcard.2005.12.006","article-title":"Statin safety: an overview and assessment of the data\u20142005","volume":"97","author":"Bays","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2011.05.005_bib8","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1161\/01.str.0000034125.94759.41","article-title":"ACC\/AHA\/NHLBI Clinical Advisory on the Use and Safety of Statins","volume":"33","author":"Pasternak","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.jacl.2011.05.005_bib9","series-title":"Biometry: The Principles and Practice of Statistics in Biological Research","author":"Sokal","year":"1995"},{"key":"10.1016\/j.jacl.2011.05.005_bib10","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"issue":"150","key":"10.1016\/j.jacl.2011.05.005_bib11","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","article-title":"Narrative review: statin-related myopathy","volume":"16","author":"Joy","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2011.05.005_bib12","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2014a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2011.05.005_bib13","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jacc.2009.04.053","article-title":"The SLCO1B1\u22175 genetic variant is associated with statin-induced side effects","volume":"54","author":"Voora","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2011.05.005_bib14","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.amjcard.2007.09.099","article-title":"Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins","volume":"101","author":"Stein","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2011.05.005_bib15","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.clinthera.2006.06.004","article-title":"Rosuvastatin 5 and 10 mg\/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies","volume":"28","author":"Glueck","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.jacl.2011.05.005_bib16","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1371\/journal.pone.0000097","article-title":"A systems biology strategy\u00a0reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle","volume":"1","author":"Laaksonen","year":"2006","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jacl.2011.05.005_bib17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1365-2710.2008.00961.x","article-title":"What do we know about the genetics of aspirin intolerance?","volume":"33","author":"Palikhe","year":"2008","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jacl.2011.05.005_bib18","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1124\/jpet.105.086462","article-title":"Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells","volume":"314","author":"Sacher","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jacl.2011.05.005_bib19","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2165\/00002018-200225120-00005","article-title":"Oxidation injury in patients receiving HMG-CoA reductase inhibitors: occurrence in patients without enzyme elevation or myopathy","volume":"25","author":"Sinzinger","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.jacl.2011.05.005_bib20","first-page":"17","article-title":"Racial differences in adherence to cardiac medications","volume":"95","author":"Charles","year":"2003","journal-title":"J Natl Med Assoc"},{"key":"10.1016\/j.jacl.2011.05.005_bib21","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1152\/jappl.1986.61.5.1758","article-title":"Skeletal muscle characteristics in sedentary black and Caucasian males","volume":"61","author":"Ama","year":"1986","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.jacl.2011.05.005_bib22","first-page":"323","article-title":"Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics","volume":"11","author":"Neuvonen","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.jacl.2011.05.005_bib23","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/mus.20291","article-title":"Molecular clues into the pathogenesis of statin-mediated muscle toxicity","volume":"31","author":"Baker","year":"2005","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jacl.2011.05.005_bib24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/0129784-200808060-00004","article-title":"Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism","volume":"8","author":"Golomb","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jacl.2011.05.005_bib25","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2011.05.005_bib26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.coph.2007.12.010","article-title":"New insights into mechanisms of statin-associated myotoxicity","volume":"8","author":"Sirvent","year":"2008","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.jacl.2011.05.005_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.trsl.2008.11.002","article-title":"Low serum 25 (OH) vitamin D levels (<32 ng\/mL) are associated with reversible myositis-myalgia in statin-treated patients","volume":"153","author":"Ahmed","year":"2009","journal-title":"Translational Res"},{"key":"10.1016\/j.jacl.2011.05.005_bib28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1468-3083.2006.01838.x","article-title":"Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review","volume":"21","author":"Noel","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jacl.2011.05.005_bib29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/mus.20871","article-title":"Physiogenomic association of statin-related myalgia to serotonin receptors","volume":"36","author":"Ruano","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jacl.2011.05.005_bib30","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/BOR.0b013e328314b7b4","article-title":"Genetic predisposition to statin myopathy","volume":"20","author":"Vladutiu","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jacl.2011.05.005_bib31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-511X-6-7","article-title":"Genetic determinants of statin intolerance","volume":"6","author":"Oh","year":"2007","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jacl.2011.05.005_bib32","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/clpt.2009.197","article-title":"Transporter pharmacogenetics and statin toxicity","volume":"87","author":"Niemi","year":"2010","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287411006076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287411006076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T09:52:28Z","timestamp":1560333148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287411006076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S1933287411006076"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2011.05.005","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}